Alexion Pharmaceuticals Inc. Reports First Quarter 2013 Results

Published: Apr 25, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results and a development pipeline update for the three months ended March 31, 2013. The Company reported net product sales of SolirisĀ® (eculizumab) of $338.9 million, an increase of 38 percent from the same period in 2012. Revenue performance for the quarter reflects steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) globally, and an increasing number of new patients with atypical Hemolytic Uremic Syndrome (aHUS) commencing Soliris treatment in the US and Western Europe.

Help employers find you! Check out all the jobs and post your resume.

Back to news